Related Experiment Video
Updated: May 30, 2026
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Poly(methyl malate) nanoparticles: formation, degradation, and encapsulation of anticancer drugs
Alberto Lanz-Landázuri1, Montserrat García-Alvarez, José Portilla-Arias
1Departament d'Enginyeria Química, Universitat Politècnica de Catalunya, ETSEIB, Diagonal 647, 08028 Barcelona, Spain.
Abstract:
PMLA nanoparticles with diameters of 150-250 nm are prepared, and their hydrolytic degradation is studied under physiological conditions. Degradation occurs by hydrolysis of the side chain methyl ester followed by cleavage of the main-chain ester group with methanol and L-malic acid as the final degradation products. No alteration of the cell viability is found after 1 h of incubation, but toxicity increases significantly after 3 d, probably due to the noxious effect of the released methanol. Anticancer drugs temozolomide and doxorubicin are encapsulated in the NPs with 20-40% efficiency, and their release is monitored using in vitro essays. Temozolomide is fully liberated within several hours, whereas doxorubicin is steadily released from the particles over a period of 1 month.
Insights
Poly(methyl 2-acetamido-2-deoxy-6-O-sulfo-α-D-glucopyranosid)uronate (PMLA) nanoparticles degrade into methanol and L-malic acid. While initially non-toxic, PMLA nanoparticles exhibit increased toxicity after 3 days due to methanol release.
Area of Science:
- Biomaterials Science
- Polymer Chemistry
- Nanotechnology
Background:
- Poly(methyl 2-acetamido-2-deoxy-6-O-sulfo-α-D-glucopyranosid)uronate (PMLA) nanoparticles are investigated for potential biomedical applications.
- Understanding the degradation pathways and biocompatibility of nanoparticles is crucial for their safe use.
Purpose of the Study:
- To characterize the hydrolytic degradation of PMLA nanoparticles under physiological conditions.
- To evaluate the in vitro toxicity of PMLA nanoparticles and their degradation products.
- To assess the drug-loading and release capabilities of PMLA nanoparticles for anticancer agents.
Main Methods:
- PMLA nanoparticles (150-250 nm) were synthesized.
- Hydrolytic degradation was studied under physiological conditions.
- Cell viability assays were performed to assess toxicity.
- In vitro drug release studies were conducted for encapsulated temozolomide and doxorubicin.
Main Results:
- PMLA nanoparticles degrade via hydrolysis of ester groups, yielding methanol and L-malic acid.
- No significant cytotoxicity was observed after 1 hour of incubation.
- Increased toxicity was noted after 3 days, attributed to methanol release.
- Encapsulation efficiency for temozolomide and doxorubicin was 20-40%.
- Temozolomide was released within hours, while doxorubicin release occurred over one month.
Conclusions:
- PMLA nanoparticles undergo hydrolytic degradation producing methanol and L-malic acid.
- The release of methanol contributes to the observed cytotoxicity after prolonged incubation.
- PMLA nanoparticles demonstrate potential as drug delivery vehicles with tunable release profiles for different anticancer drugs.
